What is the best path towards allogeneic transplantation in MDS and AML? A survey among German-spreaking centers for allogeneic hematopoietic stem cell transplantation - PubMed
5 hours ago
- #MDS/AML treatment
- #bridging strategies
- #allogeneic stem cell transplantation
- Allogeneic hematopoietic stem cell transplantation (allo SCT) offers a curative chance for high-risk AML and MDS patients, but the optimal pre-transplantation strategy is debated.
- A survey of 22 German transplant centers revealed heterogeneous preferences: upfront transplantation was favored in 68% of intermediate-risk MDS cases, while chemotherapy was preferred (64%) for bridging AML patients in remission.
- The use of hypomethylating agents (HMA) and induction chemotherapy for relapsed AML was highly controversial among centers.
- The study highlights the need for further prospective evaluation to determine the best bridging strategies before allo SCT.